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Abstract
Background: It is known that tight control of glucose in the Intensive Care Unit
reduces morbidity and mortality not only in diabetic patients but also in those
non-diabetics who become transiently hyperglycemic. Taking advantage of a recently
marketed subcutaneous glucose sensor we designed an Automatic Insulin Infusion
System (AIIS) for inpatient treatment, and tested its stability under simulated clinical
conditions.
Methods: The system included: reference glucose, glucose sensor, insulin and
glucose infusion controllers and emergency infusion logic. We carried out computer
simulations using Matlab/Simulink®, in both common and worst-case conditions.
Results: The system was capable of controlling glucose levels without entering in a
phase of catastrophic instability, even under severe simulated challenges. Care was
taken to include in all simulations the 5-10 minute delay of the subcutaneous
glucose signal when compared to the real-time serum glucose signal, a well-known
characteristic of all subcutaneous glucose sensors.
Conclusions: When tested in-Silico, a commercially available subcutaneous glucose
sensor allowed the stable functioning of a proportional-derivative Automatic Insulin
Infusion System, which was able to maintain glucose within acceptable limits when
using a well-established glucose response model simulating a patient. Testing of the
system in vivo using animal models is now warranted.
Background
Diabetes Mellitus affects 5.1 per cent of the world’s adult population [1], with a preva-
lence of up to 12.4% among hospitalized patients [2].
It has been shown that “tight control of blood glucose” (i.e. between 80 and
110 mg × dL
-1 = 4.4-6.1 mmol × L
-1) in critically ill patients reduces dramatically the
mortality from 8.0% to 4.6% in Intensive Care Unit (ICU) patients. Additionally, it
reduces bloodstream infections by 46%, renal failure by 41%, transfusions by 50% and
polyneuropathy by 44%. Interestingly, these results apply to those individuals who
-being diabetic or not- have blood glucose on admission > 110 mg × dL
-1 [6.1 mmol·L
-
1] (up to 76% of ICU patients) [3-6]. Tight control of blood glucose is also useful in
Coronary Care Units, where 33% of patients are diabetics and 33% have glucose intol-
erance. As a token of the importance of the subject, in Portland, Oregon, USA, tight
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50%, hospital stay by 56% and mortality by 67% in diabetic patients who underwent
open heart surgery [7].
The current standard of care for hospitalized diabetic patients (Figure 1) requires the
measurement of capillary blood glucose at least 4 times a day, and by the use of a
Figure 1 Current in-patient management of intravenous insulin infusion. Current in-patient
management of intravenous insulin infusion(see text) Nurses have to measure capillary blood glucose
every 1-6 hours, and after manually recording date, time and value, they read a “slide scale” previously
estimated by the attending physician, that helps them to adjust the insulin infusion rate for the next
period.
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means of an infusion pump. In cases in which “tight control” is needed, capillary blood
sampling has to be done every hour, increasing personnel workload. Hypoglycemia
(i.e., serum glucose < 60 mg/dl) is a frequent side effect, and must be corrected by
intravenous glucose.
Thus, there is a need for automated protocols of intravenous insulin administration
for hyperglycemic patients in the ICU [8,9].
In this context, we studied the behavior of an automated intravenous insulin infusion
system (AIIS) designed by the authors, that uses an FDA-approved subcutaneous glu-
cose sensor [10,11]. This sensor has been shown to be useful for outpatient care by
enabling individuals with type-1 diabetes to manually adjust their subcutaneous insulin
doses according to the glucose levels displayed by the device [11,12].
Our aim was to use Matlab/Simulink® to develop a computer program for the AIIS,
and to challenge this system repeatedly in a fashion that in some cases was similar to
the worst clinical conditions possible to find in patients with diabetes in the ICU.
What we considered a success was the AIIS being able to control blood glucose with-
out becoming instable even in the worst conceivable circumstances.
Our concerns about potential instability of the AIIS originated in a characteristic of
the subcutaneous glucose sensor, i.e. its 5 to 10-min. delay when compared to changes
in blood glucose. We hypothesized that this delay, by altering the phase of feedback
loop of the AIIS, could result in catastrophic instability. However, the results of the
simulations showed that the system behaves with a high level of stability under a wide
range of clinical conditions likely to be encountered in the ICU setting.
Methods
I. Architecture of the AIIS
Our closed-loop control system is shown in Figures 2 and 3. The glycemia of the
patient acquired by the glucose sensor [13,14] is compared with a desired (reference)
blood glucose level and the difference between these two values (the error) is pro-
cessed by the controller, generating the signals for the actuators (insulin and glucose
[dextrose in water] pumps).
I-A. Reference Glycemia
Normal fasting glycemia in adults varies between 70 and 99 mg × dL
-1.I nt h ec a s eo f
an hospitalized patient, clinicians tend to keep the glycemia (G) below 120 mg × dL
-1,
but away from hypoglycemia. As symptoms of hypoglycemia start at G <6 0m g×
dL
-1, we set the reference level at 100 mg × dL
-1, with an acceptable range of 90 to
120 mg × dL
-1,n e a rt h e“tight control” of blood glucose level (80-110 mg × dL
-1)a n d
safely away from hypoglycemia.
I-B Glucose Sensor
We choose the Medtronic Minimed (California, USA) Continuous Glucose Monitoring
System (CGMS), a subcutaneous needle sensor capable of providing readings represen-
tative of blood glucose concentrations every 10 seconds, that are averaged every 5 min-
utes, totalizing 288 glucose values per day, to be either stored or displayed [11,13,14].
Its operation is based on the oxidation of glucose in the presence of oxygen and the
enzyme glucose oxidase, generating an electrical current that is proportional to inter-
stitial and blood glucose levels.
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physician-supervised analysis. Its version with glucose reading display [10] allows
patients to manually modify their own subcutaneous insulin dose (when using syringes)
or infusion rate (when using a wearable insulin pump).
Based on the work of Chee et.al. (on the use of CGMS in critically ill patients) [15],
and of Steil et.al. [16], we have developed a mathematical model of the CGMS sensor.
For a sensor signal S(t) reacting to glucose level G(t) with sensitivity a (nano Ampères
per mg/dL), the model equation becomes,

dS t
dt
St Gt T D
()
() ( ) , =− + − (1)
In equation 1, τ is the time constant that defines an immediate proportional
response, and operationally represents the time elapsed for the signal from the sensor
to reach 63% of the equilibrium when compared to the intravenous glucose concentra-
tion. TD is a transport lag [16]. A white Gaussian noise to the sensor signal was added
to our model, assuming a mean = 0.0 and a variance = 100 [17].
In their publication, Steil et. al. [16] included a graph of the simultaneous measure-
ment of plasma and subcutaneous glucose, showing no transport lag (i.e., TD =0 . 0 )
[16,18]. Of the two glucose sensors presently being developed by Medtronic Minimed,
the subcutaneous glucose sensor has been shown to have a time constant ranging from
2 to 12 min. The graph by Steil et.al. depicted a time constant (τ)o f5 . 7 7m i n u t e s
[16,18], which is thought to be primarily related to interstitial glucose equilibration.
a in equation 1 is equal to 0.23 nA × [mg × dl
-1]
-1 [19]. Using data provided by the
manufacturer we included lower and upper limit saturations of 40 and 400 mg × dl
-1,
respectively.
Figure 2 System diagram of the “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment.
System diagram of the “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment(see text). Glucose
concentration measured by the subcutaneous sensor is compared to the reference glycemia (100 mg/dL).
The result becomes the input for the controller. If the result is either normoglycemia (90-120 mg/dL) or
hyperglycemia (> 120 mg/dL), or if the glycemia is rising too fast, then the controller signals the insulin
pump, that releases insulin solution at a particular rate (international units per hour). On the other hand, if
the input to the controller reflects a hypoglycemia (i.e., glycemia < 60 mg/dL), or if the glycemia, albeit
being within normal range, is falling too fast, then the controller signals the glucose pump. Every five
minutes, the subcutaneous glucose sensor submits the results of a new glucose estimate to the input of
the controller, and the whole process is repeated.
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Page 4 of 19Figure 3 “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment: Proposed architecture.
Proposed architecture of the “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment (see text). The
nano amperimetric current produced by the subcutaneous glucose sensor located at the forearm of the
patient, is shown entering an analog-digital converter. This device has two tasks. (a) To continuously
measure the current from the sensor, and average it every five minutes, and (b) to transform the 5-minute
average into a digital signal, that is submitted to the computer (where the controller is located) by means
of an USB cable. From the computer, two USB cables are connected to infusion pumps, one for insulin,
and the other for glucose solution. Note the low-dead-space catheter placed in a vein of the forearm of
the patient. The low dead space allows for a rapid transition from insulin to glucose infusion and vice-
versa.
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The controller of the AIIS can be divided into three main parts: the insulin infusion
pump controller, the glucose infusion pump controller, and the emergency infusion
logic (Figures 2 and 3).
The insulin infusion pump controller is based on the algorithm proposed by Marliss
et.al. in 1977[20], in the form later published in 1981 by Broekhuyse et.al. [21], whose
original equations were as follows,
IR M S G DF B =+ + − () () ⎡
⎣
⎤
⎦
1
2
1 0 tanh , (2a)
IR
IR if G G
IR if G G
crit
crit
=
≥
<
⎧
⎨
⎪
⎩ ⎪
’,
. min
0
0
(2b)
In equation 2a, IR is the insulin infusion rate effectively being pumped [mU ×
min
-1], M is the maximum infusion rate possible [mU × min
-1], S [dL × mg
-1]i st h e
slope of the hyperbolic tangent curve, and B [mg × dL
-1] is the blood glucose level at
which half maximum infusion rate is chosen to occur (as determined from the tanh
function curve).
In equation 2b (see “Emergency Infusion Logic”,b e l o w ) ,I R ’ is the infusion rate in
ml × hr
-1 as determined by the insulin infusion controller, G0[mg × dL
-1]i st h el a s t
available average glycemia, Gcrit is the critical serum glucose level in mg × dL
-1 below
which intravenous glucose infusion must begin, (see also “glucose infusion controller”
and equation 6, below), and IRmin [mU × min
-1] is the minimum rate of insulin
infusion.
In equation 2a, DF is the Differential Factor [mg × dL
-1], which is computed as,
DF K A K A =+ 1
3
2 , (3)
where the parameters K1 = 1 [mg × dL
-1]
-2 and K2 = 10 [nondimensional] [21], and
the original method for calculating A [mg × dL
-1] is as follows,
AG G G G =− − − ()
1
10
4 0123 , (4)
where Gi [ m g×d L
-1] is the average glycemia determined i minutes ago.
Since the CMGS System provides one measurement of glycemia every 5 minutes
rather that at every minute, we propose the following modification of equation (4):
AG G G =−+ 0 1965 0 2136 0 0171 051 0 ... , (5)
where G0 [mg × dL
-1] is the last reading of glycemia, and G5 and G10 are the pre-
vious readings [mg × dL
-1] five and ten minutes earlier respectively. The coefficients
accompanying the glycemia readings were obtained using as a reference the experi-
mental data published by Broekhuyse et.al. [21] and the glycemia and insulinemia pro-
files from a 69.5 Kg male type 1 diabetic patient being controlled by the artificial
pancreas of Albisser et.al. [22,23] which used the algorithms corresponding to the
aforementioned equations (2),(3) and (4). Needing blood samples for serum glucose
every minute, Albisser’s artificial pancreas was able to function for a limited period of
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emulate its profile, but using the three glycemia readings obtained every 5 minutes as
s h o w ni nE q u a t i o n( 5 ) .W i t hA l b i s s e r ’s data and the least square approach to find the
optimum parameters, we reproduced the glycemic control as shown in Figure 4, but
using equation (5) instead of equation (4).
From the point of view of the control theory, considering the current glycemia in
addition to the differences with previous values in equations (2), (3) and (5), allowed
us to build a proportional-derivative control model, as reviewed by Parker et. al. [24].
The Glucose Infusion Pump Controller: This subsystem was included in our AIIS as
an emergency measure to avoid hypoglycemia. In normal circumstances, the insulin
infusion alone should be enough to keep an adequate glycemic control. This emer-
gency subsystem is activated when serum glucose falls below 60 mg × dL
-1 (hypoglyce-
mia). It has been determined that for the glucose infusion in these circumstances,
proportional control (P) provides adequate performance [25]. The controller equation
is given by equation 6,
GR K G G Gc r i t =− () 0 , (6a)
GR
if G G
GR if G G
crit
crit
=
≥
<
⎧
⎨
⎪
⎩ ⎪
0 0
0
,
’.
(6b)
where GR is the glucose infusion rate in ml × h
-1, Gcrit is the critical serum glucose
level in mg × dL
-1 below which the infusion must begin, and G0 is the last 5-minute-
averaged glycemia reading. KG is the controller gain. GR is always positive because the
controller activates itself only when G0 falls below Gcrit. The definition of GR’ is given
in the next paragraph, below.
Emergency Infusion Logic: It has been included in our system to both shut down the
insulin infusion to a minimum and activate the glucose infusion whenever a critically
low glycemia (Gcrit) is detected. Once the glycemia returns to a value that is above the
critical level, insulin infusion returns back to normal operation and glucose infusion is
disabled. The activation or deactivation of each of the infusion pumps were summar-
ized in equation 2b for insulin (see above) and in equation 6b for glucose, where GR′
is the infusion rate in ml × hr
-1 as determined by the glucose infusion controller, and
GR is the infusion rate effectively leaving the glucose pump.
The insulin infusion has a minimum value that is different from zero (i.e. IRmin≠ 0;
see Equation 2, above) for two reasons. First, considering that the insulin and glucose
infusions take place through a catheter inserted in a vein, it is essential to ensure a
minimum permanent flow to avoid the occlusion of the catheter (KVO, “keep vein
open” feature). Second, in diabetic patients lacking endogenous production of insulin
(Type-1 diabetes mellitus), it is essential to ensure a minimal serum concentration of
insulin in order to avoid a massive lipolysis with ensuing ketoacidosis.
I-D Actuators
As described above, the AIIS has two infusion mechanisms regulating blood glucose
concentration: insulin infusion and glucose infusion using the IMED Gemini PC-1
infusion pump produced by Alaris Medical Systems (San Diego, CA, U.S.A.). This
pump fulfills the specifications of our system in terms of range of infusion rate,
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Page 7 of 19Figure 4 “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment: Simulation of mild
positive challenge. “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment: Simulation of mild
positive challenge given by a standard meal containing 50 grams of carbohydrate in a 70-Kg patient with
Type-1 Diabetes Mellitus and average hepatic sensitivity (Sh = 0.5). See also fifth row in Table 1. (A)
Glycemia [mg × dL
-1]. The arrow shows the start of the mild positive challenge. The black area under the
curve shows an overshoot that after reaching a peak at 150 mg × dL
-1, lasts for 30 minutes. The time it
takes for the blood glucose to return to a value just below 120 mg × dL
-1 is 90 minutes (TS = 90 minutes).
(B) The insulin infusion rate moves around an average of 1.0 I.U. × h
-1 before the challenge, i.e. around 0.35
I.U. per Kilogram of body weight in a 70-Kg individual, which is the normal basal insulin secretion (see the
text). After the challenge, the insulin infusion rises up to 7.0 I.U. × h
-1 during 90 minutes. Please observe
that the insulin infusion rate is not a continuous function but a step function representing orders given by
the controller to the clinical infusion pumps, whose flow rate has to be adjusted by steps not smaller than
0.1 mL × h
-1 (see “Actuators”, part I-D in methods section, above). (C) The estimated serum insulin
concentration moves around an average of 20.0 μI.U. × mL
-1 before the challenge, and then rises up to 55
μI.U. × mL
-1 for 90 minutes.
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for the simulations considered a minimum infusion rate of 1.0 ml × h
-1, a maximum
rate of 500 ml × h
-1,a n dr a t es t e p so f0 . 1m l×h
-1 [26]. Although the IMED Gemini
PC-2 model could have been more convenient due to its double channel capacity that
allows the infusion of two solutions simultaneously and independently, for simplicity
we used two separate IMED Gemini PC-1 pumps. (Figure 3).
I-E Diabetic Patient
In order to carry out the computer simulations aimed to test the behavior of our sys-
tem, we used a mathematical model of human glucose physiology based on the work
by Lehmann, Deutsch & Hermanyi [27,28], which assumes a patient completely lacking
endogenous insulin secretion. It contains a single compartment of extracellular glucose,
where it enters via both intestinal absorption and hepatic glucose production. Similarly,
the gastric emptying rate that provides the glucose flux from the stomach to the small
intestine is controlled by a process defined as a function of the carbohydrate content
of the ingested food. The glucose is removed from the extracellular space by insulin-
independent utilization in the central nervous system and red blood cells, and also by
the insulin-dependent utilization by the liver and peripheral tissues (muscle and fat).
Additionally, glucose excretion is considered to take place through the kidneys when
the glycemia exceeds renal glucose threshold.
The model accounts separately for the glucose entering the peripheral tissues and the
glucose entering/leaving the liver, an approach that allows to assign a range of values
to patient-specific parameters, such as hepatic insulin sensitivity [26,27]. In this con-
text, the model summarizes the glucose processing by the liver as the net hepatic glu-
cose balance (NHGB), which is the algebraic sum of the glucose produced by both
neoglucogenesis and glycogen breakdown, minus the glucose removed by glycogen
synthesis. The NHGB is a function of both the glucose and the insulin plasma concen-
trations (see below) [29].
In fact, the Lehman & Deutsch model is based on four equations. The first one is a
differential equation describing the change in plasma insulin concentration (dI/dt). The
second is also a differential equation that now describes the build-up and deactivation
of the active insulin pool (dIa/dt). The third and fourth equations describe the rate of
insulin absorption from the subcutaneous tissue. As our AIIS injects insulin directly
into the bloodstream, we did not use these last two equations. On the other hand, the
overall rate of peripheral plus insulin-dependent glucose utilization (Gout ,m g×K g
-1 ×
h
-1) depends on an equation whose two main variables are the current glucose level
(G, mg × dL
-1) and the insulin concentration (I*eq , mU.I. × L
-1). In the same equation,
the most important constant is the slope of peripheral glucose utilization versus insulin
line (c, 0.045 mg × min
-1 × mIU
-1 × L).
When the patient eats carbohydrates, the Lehman & Deutsch model allows for calcu-
lation of the rate of change of glucose in the gut (Ggut ,m g×d L
-1), which depends on
the glucose load and the rate of gastric emptying. This Ggut in turn, allows the contin-
uous calculation of the systemic appearance of glucose via absorption from the gut
(Gin ,m g×d L
-1 ×h
-1).
The NHGB (mg × h
-1), which can be either positive or negative, depends on effective
plasma insulin, that is, plasma insulin (I*eq ,m U . I .×L
-1), times the patient-specific
hepatic insulin sensitivity (Sh), an adimensional number that has a normalized value
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effective insulin level.
Finally, the change of glycemia with time (dG/dt, mg × dL
-1 ×h
-1 )i sg i v e nb ya
differential equation depending on Gin(t), plus NHGB(t), minus Gout(t), and minus
Gren(t). Where Gren is the rate of renal excretion of glucose (mg × h
-1).
The main advantage of the Lehman & Deutsch model resides in its explicit anatomi-
cal compartments, taking into account the function of the body organs involved. For
the same reason, it is easy to introduce modifications in the model, as it was necessary
with our own simulations. The Lehman & Deutsch model was validated clinically in
1994 by their own authors [27].
More recently, others [30] have tried to improve the understanding of the glucose-
insulin interactions by means of an approach based in 4 unit processes, i.e., liver, gas-
trointestinal tract, muscle & adipose tissue and beta cell. In our view however, this
interesting new model underestimates the endogenous glucose production [31,32].
II.- Simulations of the Behavior of the AIIS in Hospitalized Patients
To test the behavior of the AIIS in normal and in the worst possible scenarios, we
designed the series of cases summarized in tables 1 and 2. Simulations were carried
out in Matlab/Simulink® v6.5 from Mathworks Inc., using a Pentium IV 1,800 MHz
computer, equipped with 256 MB RAM. Under these conditions, each 24-hour simula-
tion took about 15 seconds to complete.
Results
I Positive Challenges
Table 1 shows the positive challenges that we expected to be controlled by the AIIS,
i.e. all perturbations tending to increase glycemia. We assumed that a single perturba-
tion occurred at the hour 10:00 within the 24-hour simulation span.
I-A Mild Challenge
The mild challenge simulates a patient eating normally an average meal, containing
50 grams of complex carbohydrates (starch), the digestion of which allows the glucose
to enter the bloodstream in a slow fashion. As shown in Table 1 and in Figure 4-A, in
the case of a 70-Kg diabetic with average hepatic sensitivity (Sh = 0.5), the glycemia
rises temporarily to a level close to 150 mg × dL
-1, comparable to the transient eleva-
tion of serum glucose after a meal in a normal adult. As soon as the AIIS detects this
rise in glycemia, the insulin infusion rate rapidly increases in concordance with the
derivative component of the control algorithm (Figure 4-B). The same algorithm
makes insulin infusion rate to decrease sharply as soon as the first derivative of the
glycemia reaches the positive-to-negative critical point, without falling below 1 ml × h
-
1, thus avoiding the risk of ketoacidosis (a complication that might arise if plasma insu-
lin concentration was allowed to fall below 0.5 μU×m l
-1). In fact, as shown in Figure
4-C, plasma insulin never falls below the lower limit of the normal fasting range (6-26
μU×m l
-1) [33]. Furthermore, the aforementioned minimal infusion rate of 1 ml/hr
corresponds to the parameter “K.V.O.” of the IMED Gemini PC-1 infusion pump. The
lack of an undershoot of glycemia after this mild challenge precluded the glucose
infusion to start.
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Overshoot
(Glycemia > 140 mg × dL
-1)
Undershoot
(glycemia < 60 mg × dL
-1)
Type of
Challenge
Weight
(Kg)
Hepatic
Sensitivity (Sh)
Peak
(mg × dL
-1)
Duration
(min)
TS*
(min)
Peak
(mg × dL
-1)
Duration
(min)
TS*
(min)
0.7 144 38 72 no no n/a
80 0.5 154 72 95 no no n/a
0.3 168 102 144 no no n/a
0.7 144 30 90 no no n/a
Mild ¶ 70 0.5 150 30 90 no no n/a
0.3 163 84 135 no no n/a
0.7 143 22 42 no no n/a
60 0.5 150 46 66 no no n/a
0.3 159 72 108 no no n/a
0.7 164 54 72 no no n/a
80 0.5 172 76 92 no no n/a
0.3 182 86 108 no no n/a
0.7 163 50 70 no no n/a
Moderate § 70 0.5 170 30 60 no no n/a
0.3 181 78 96 no no n/a
0.7 162 50 70 no no n/a
60 0.5 170 58 72 no no n/a
0.3 183 72 84 no no n/a
0.7 170 30 31 no no n/a
80 0.5 176 36 37 no no n/a
0.3 177 41 42 no no n/a
0.7 175 30 55 no no n/a
Severe † 70 0.5 180 15 120 no no n/a
0.3 191 36 39 no no n/a
0.7 189 30 31 no no n/a
60 0.5 188 29 30 no no n/a
0.3 201 36 38 no no n/a
Note the inter-individual variations with body weight and/or hepatic sensitivity changes.
(bold) The two rows in bold numbers are the ones represented in Figures 4 and 5 respectively
(*) TS = settling time, minutes for the glycemia to return to the 90-120 mg × dL
-1 range
(¶) Mild challenge = 50 g of oral carbohydrate (from 50 g of starch)
(§) 50 g of oral glucose (250 g of grapes)
(†) 10 g intravenous glucose (20 mL of 50% dextrose in water) in 30 seconds
Table 2 Negative challenge in 70-Kg type-1 diabetics
Undershoot
(glycemia < 60 mg × dL
-1)
Overshoot
(Glycemia > 140 mg × dL
-1)
Challenge Hepatic
Sensitivity
(Sh)
Peak
(mg × dL
-1)
Duration
(min)
TS*
(min)
Peak
(mg × dL
-1)
Duration
(min)
TS*
(min)
10 units of regular insulin
administered intravenously
in 2 seconds
0.7 10 2 22 no no n/a
0.5 12 5 60 no no n/a
0.3 31 7 45 no no n/a
Note the inter-individual variations with hepatic sensitivity changes.
(*) TS = settling time, minutes after the start of the challenge for the glycemia to return to the 90-120 mg × dL
-1 range
Ortiz et al. BioMedical Engineering OnLine 2010, 9:35
http://www.biomedical-engineering-online.com/content/9/1/35
Page 11 of 19I-B Moderate Challenge
A moderate positive demand was given by the ingestion of 50 grams of glucose in the
form of 250 grams of grapes. As seen in the 14
th row of Table 1, in the case of a
70-Kg diabetic with average hepatic sensitivity (Sh = 0.5) the glycemia rose rapidly up
to a value close to 170 mg × dL
-1, and a peak duration of 30 min. The hyperglycemia
was then controlled by the AIIS by means of a sharp and sustained increase in the
insulin infusion rate, that corrected glycemia after a TS of 60 minutes. As with the
mild challenge, only the insulin infusion was required whereas the glucose pump
remained inactive.
I-C Severe Challenge
For the severe positive challenge we selected the most abrupt method of administering
glucose to a patient: injecting 20 ml of 50% dextrose-in water into the subclavian vein
in 30 seconds. As seen both in the 23
d row of Table 1 and in Figure 5, in the case of a
70-Kg diabetic with average hepatic sensitivity (Sh = 0.5), a very steep rise in glycemia
ensued after glucose injection (Figure 5-A). The fast rise in the insulin infusion rate
that was ordered by the AIIS controller (Figure 5-B) was able to keep the hyperglyce-
mic overshoot within tolerable limits, i.e., 180 mg × dL
-1 for 15 minutes. For some
minutes after the end of the sharp insulin response, serum insulin remained high
(Figure 5-C), resulting in a reduction in serum glucose to levels below 90 mg × dL
-1,
but without reaching a true undershoot value thanks to (a) a 45-minute period of
minimum insulin infusion(KVO), and (b) the activation of the glucose pump. After a
TS of 120 minutes, serum glucose returned to the 90-120 mg × dL
-1 range.
I-D Inter-Individual Variation In The Performance of the AIIS
In the year 1994, when the Lehman & Deutsch model was validated clinically, two
parameters, Sh y Sp, were introduced in order to reduce the differences between
observed and predicted blood glucose. Sh y Sp are, respectively, hepatic and peripheral
sensitivities to insulin. Both are adimensional numbers ranging from 0.0 to 1.0.
In order to explore the inter-individual variation in the behavior of the AIIS, we
challenged our own model for patients with body weight above and below 70 kg, and
hepatic sensitivity (Sh ) above and below 0.5 (Table 1). For the mild positive challenge,
the overshoot varied between 143 and 168 mg × dL
-1, lasting for 22-102 min., with set-
tling times between 42 and 144 min. For the moderate positive challenges, the over-
shoot varied between 162 and 183 mg × dL
-1, lasting for 30-86 min., with settling
times between 60 and 108 min.
For the severe positive challenges, these figures were: overshoot of 170-201 mg ×
dL
-1 , lasting 29-41 min., with a settling time of 30-120 min. There were no “bounce
back” undershoots.
II Negative Challenges
Table 2 shows the negative challenge (a perturbation that tends to decrease glycemia)
that we expected to be controlled by the AIIS. We assumed that this occurred at the
hour 10:00 as a single perturbation within the 24-hour simulation span. The strong
negative challenge was the intravenous injection of 10 units of regular insulin. To put
this in mathematical terms, we applied the two-compartment model for intravenous
insulin bolus described by Kobayashi et al. [34], using the parameters shown in their
Appendix A. After injection, serum insulin concentration rose to 3,300 μU×m l
-1 ,
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Page 12 of 19Figure 5 “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment: Severe positive
challenge. “Automatic Insulin Infusion System” (AIIS) for Inpatient Treatment: Severe positive challenge
given by the sudden intravenous injection of 10 grams of glucose into a 70-Kg patient with Type-1
diabetes mellitus and average hepatic sensitivity (Sh = 0.5) as shown in the 23
d row of Table 1. (A)
Glycemia [mg × dL
-1]. The arrow shows the start of the severe positive challenge. The black area under the
curve is the overshoot that lasts for 15 minutes. Although the time it takes for the blood glucose to return
to a value just below 120 mg × dL
-1 is 16 minutes, the real TS = 120 minutes, which is the time it takes for
the system to stabilize itself within the 90-120 mg × dL
-1 range. There is no undershoot, as the glycemia
does not fall below 60 mg × dL
-1. (B) As in the case of figure 4-B, the insulin infusion rate moves around
an average of 1.0 I.U. × h
-1 before the challenge. Immediately after the challenge, the insulin infusion rises
up to 12.0 I.U. × h
-1 during 15 minutes. This was followed by minimal infusion rate for the next 45 minutes
(KVO for the Abbott pump) in order to avoid excessive hyperinsulinemia (see 5-C, below). Please observe
that the insulin infusion rate is not a continuous function but a step function representing orders given by
the controller to the clinical infusion pumps, whose flow rate has to be adjusted by steps not smaller than
0.1 mL × h
-1 (see “Actuators”, part I-D in methods section, above). (C) The AIIS response to the severe
positive challenge produced a period of hyperinsulinemia that lasted for 55 minutes. The elevated levels of
serum insulin were the result of the sharp increase in insulin infusion (as shown in 5-B, above), and its
duration was limited to 55 minutes thanks to the 45-minute period of minimal insulin infusion that ensued.
The result was a undershoot-free normalization of glycemia.
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-1. However, once more the controller of
the AIIS responded instantly, both by almost stopping insulin infusion (down to
“KVO”) and aggressively activating glucose infusion. As a result, the undershoot (glyce-
mia < 60 mg × dL
-1) was corrected after 5 min., with a Ts of 90 minutes for it to
return to the 90-120 mg × dL
-1 range.
In Table 2, in the same 70-Kg patient having hepatic sensitivities (Sh ) of 0.7 and 0.3,
the negative challenge produced glycemias of 10 and 31 mg × dL
-1 respectively, that
lasted 2 and 7 min., with settling times of 22 and 45 min.
Discussion
A quarter of a century ago, the introduction of capillary blood glucose monitors
allowed Type-1 diabetics to intermittently measure their glycemia and adjust their sub-
cutaneous insulin dosage 3 to 4 times a day using empirical algorithms. This so-called
“Intensified Insulin Therapy”, currently the standard of care for outpatients and an
example of “open-loop glucose control”, has resulted in a significant reduction in
chronic microvascular complications in diabetic patients [35,36]. Continuous glucose
monitoring became possible in 1999 by means of the Continuous Glucose Monitoring
System (Medtronic Minimed CGMS, Northridge, CA, USA) [10,19]. In the last 5 years,
the subcutaneous glucose monitoring systems using microdialysis (GlucoDay, A.
Menarini Diagnostics, Italy) [37] and an improved version of the Medtronic Minimed
CGMS (Guardian® RT) were introduced allowing real-time glucose readings [11]. In
the year 2006, R. Hovorka [38] summarized 15 clinical studies of closed-loop control
in Type 1 diabetics carried out between 1960 and 2004, of which at least nine used
subcutaneous sensors. These studies were oriented to outpatient Type-1 diabetics; with
insulin being administered either subcutaneously or intraperitoneally according to
empirical, semi-automatic and automatic algorithms.
The reader might argue why we have concentrated ourselves on intravenous insulin
infusion in hospitalized patients (IVII-H), instead of modeling a system of continuous
subcutaneous insulin infusion (CSII-H).
Although CSII has been used in outpatients as well as in hospitalized patients, its use
is not advisable in patients requiring Intensive & Intermediate Care, due to the impre-
dictable absorption of insulin from the subcutaneous tissue due to vasoconstriction.
The Intravenous Insulin Infusion, on the contrary, allows for 100 per cent bioavailabil-
ity of insulin even in patients with decreased perfusion of subcutaneous tissues.
In the methods section, we mentioned the use of the Lehman & Deutsch [26,27]
model, in our view a valid choice, considering that some more recent approaches to
glucose metabolism tend to underestimate endogenous glucose production at zero
insulin [30-32].
As it was mentioned in the introduction, our aim was to explore the closed-loop glu-
cose control under conditions observed in ICU patients. The AIIS included a subcuta-
neous sensor with the characteristics of the Guardian® RT (Medtronic Minimed) and
two infusion pumps for the intravenous administration of regular insulin or glucose.
Our “Automatic Insulin Infusion System“ proved to be stable even when subjected to
the worst conceivable challenges in the clinical setting.
Our main concern when modeling our AIIS was the possibility of catastrophic
instability due to the 5-10 min. delay of the subcutaneous glucose sensor. From the
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instability is precisely the delay in the feedback subsystem. The fact that the AIIS did
not become instable even with the worst worst-case challenges, encourages our team
to take the next step, i.e., to build a prototype for animal testing.
With respect to the negative challenge, we observed that, the higher the insulin sen-
sitivity, the deepest the glycemia undershoot was, being compensated by a shorter
hypoglycemia, and shorter settling times.
In the future, other protocols, perhaps a “Model Predictive Control” (MPC) might be
used for inpatient automatic insulin infusion systems, as it has been already proposed
for both intravenous [24] and subcutaneous [35,39] closed-loop insulin infusion sys-
tems. In fact, MPC for subcutaneous insulin infusion has already been tested by Schal-
ler et. al. [40], who used either intravenous or subcutaneous (simulated by a 30-minute
delay) glucose measurements. As we have used only intravenous insulin infusion in
our in-Silico model of the AIIS, the MPC system of Schaller et.al. will need to be
adapted for intravenous insulin when used in hospitalized patients.
We are aware that the subcutaneous glucose sensors that constitute the essential
components of all continuous glucose monitoring devices do not perfectly reflect
changes in blood glucose. In fact, during euglycemia, the mean absolute relative differ-
ences (MARD’s) have been proven by others to be, respectively, 15.2, 21.2, 15.3 and
15.6 per cent, for the four currently available CGMs, i.e., Guardian (Medtronic, North-
ridge, CA, USA), Dexcom (DexCom, San Diego, CA, USA), Navigator (Abbott Diabetes
Care, Alameda, CA, USA), and Glucoday (A. Menarini Diagnostics, Florence, Italy). Of
these, the first three are subcutaneous needle-type, and the last one uses a microdyaly-
sis system [41]. However the needle-type system that we decided to include in our
model (the same as the one used in Guardian®) has an accuracy that is not significantly
different from the others [41], and constitute now the best available choice.
Comparison of the performance of the AIIS to other existing solutions can be done
at three different levels:
In the first level, the averaged results of 1583 ICU patients in 12 “expert-based con-
trol studies” reviewed by Moijering S., et.al. [42] were compared with the results of the
AIIS. These studies used sliding scale or titration-based protocols developed on the
basis of previous clinical experience [43]. Their reported mean blood glucose of 7.92 ±
1.32 mmol × L
-1 (142.6 ± 23.7 mg × dL
-1) was obtained with capillary sampling every
1.44 - 3.0 hours. On the other hand, our proposed AIIS was aimed to a lower blood
glucose of 100 mg × dL
-1 (90 to 120 mg × dL
-1), was not dependent on repeated blood
sampling, and had a more rigorous criteria for hypoglycemia (i.e., < 60 mg × dL
-1).
At the second comparison level are the “model-based methods”. In the year 2008,
Chase et.al. [43] published the results of their SPRINT (Specialized Relative INsulin
and Nutrition Tables), that regulated insulin administration by being fed data (both
current and during the previous 1-2 hours) from 3 sources, i.e., (a) capillary glucose
(every 90 minutes); (b) intravenous boluses of insulin over 15-30 seconds, and (c) ent-
eral nutrition by nasogastric tube (not exceeding 90 mL × hour
-1). The SPRINT has
the merit of having been clinically tested [43,44], albeit with an average of 16 capillary
samples per day. However, the SPRINT has been designed for tube-fed patients only.
The third comparison level is the “artificial pancreas”, of which there is only one in
current clinical use - the Japanese STG-22. This device is composed of three main
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intravenous solutions of insulin or glucose. The sensor system obtains blood samples
every 5 minutes by means of an indwelling double-lumen catheter, that conducts the
blood towards a glucose-oxidase sensor. The glucose data is fed into the computer,
programmed with a proportional-derivative algorithm whose output controls the deliv-
ery of insulin or glucose to the patient. Since the year 1983, the STG-22 has been used
in more that 14,000 patients, including clinical and experimental applications [45]. The
single and most transcendental difference with our AIIS is the glucose sensing system,
as our device, instead of relying on repeated blood sampling, uses a much less invasive
subcutaneous glucose sensor.
Conclusions
The fact that after severely challenging the AIIS it did not become instable, even in the
context of using a subcutaneous glucose sensor with a 5 to 10 min. delay, means to us
that a prototype can be constructed for animal testing, under the expectations of using
it in the ICU setting in order to achieve tight control of blood glucose without fre-
quent blood sampling.
Indeed, we believe that the closed-loop control, with subcutaneous glucose sensing
(Figure 6) and intravenous insulin administration constitutes a promising approach for
developing new devices oriented to the tight control of glycemia in hospitalized
patients, particularly in the intensive care unit. This approach has two advantages.
First, it provides a new tool to reduce mortality and morbidity in the ICU. Last, but
not least, this system shall be tested in an environment with highly trained personnel
and 24-hour surveillance, so the experience thus gained might one day extend its bene-
fits to the outpatient setting, i.e., to millions of insulin-requiring diabetics worldwide.
Figure 6 A commercially available subcutaneous glucose sensor. Five views (A, B, C, D and E). (A) A
commercially available subcutaneous glucose sensor. (B) Exploded-view of a generic glucose sensor
structure. (C) The tip of the glucose sensor with its three layers. (D) The glucose sensor needle placed
under the skin in the subcutaneous tissue, where the electrochemical reaction produces a DC current
(nano-Amperes) that is directly proportional to the glucose concentration. (E) Response of the Medtronic
Minimed subcutaneous sensor (thin line) to a step change in serum glucose (black circles) (re-drawn from
data in Ref. [16])
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Page 16 of 19List of Abbreviations used
a: (greek letter alpha) Sensitivity (nA × [mg × dl
-1]
-1) [Eq. 1]; A, Differential Para-
meter (mg × dL
-1) [Eq. 4 and 5]; AIIS: Automatic Insulin Infusion System (for inpati-
ent treatment); B: Blood glucose level (mg × dL
-1) at which half-maximum infusion
rate is chosen to occur [Eq. 2a]; CGMS: Continuous Glucose Monitoring System; DF:
Differential Factor (mg × dL
-1) [Eq. 2a and 3]; FDA: Food and Drug Administration
(USA); G: Glycemia (blood glucose concentration, mg × dL
-1)[ E q .1 ] ;G 0: Last 5-min-
ute averaged glycemia (mg × dL
-1)[ E q .5a n d6 ] ;G crit: Critical glycemia (mg × dL
-1)
below which the glucose infusion controller activates itself [Eq.2b and 6b]; Gi: Glyce-
mia (mg × dL
-1) determined “i” minutes ago [Eq. 4 and 5]; GFR: Glomerular Filtration
Rate (mL × min
-1), a measure of renal function; GLUT-4: Glucose Transporter - 4
(present in muscular and adipose tissues); GR: Glucose infusion rate (mL × h
-1)[ E q s .
6a and 6b]. Note that it is in milliliters per hour (and not in mL × min
-1) as the com-
mercially available pumps are graduated in this way; GR’: Infusion rate in mL × h
-1 as
determined by the glucose infusion control l e r[ E q .6 b ] ;I C U :I n t e n s i v eC a r eU n i t ;I R :
Insulin Infusion Rate (mIU × min
-1)[ E q . 2 ] ;I R ’: Insulin infusion rate (mL × h
-1) deter-
mined by the insulin infusion controller; K1: = 1 [mg × dL
-1]
-2 , a parameter [Eq. 3]
[21]; K2: = 10 [adimensional], a parameter [Eq.3] [21]; KG: Controller gain ([mL × h
-1]
× [mg × dL
-1]
-1) [Eq. 6a]; KVO: “Keep Vein Open”. Minimal infusion rate (= 1.0 mL ×
h
-1) needed to keep venous access from being occluded by thrombosis; M: Maximal
possible insulin infusion rate (mIU × min
-1) [Eq. 2]; NHGB: Net Hepatic Glucose Bal-
ance (mg × min
-1); SGM: Subcutaneous Glucose Monitor; S: Slope (dL × mg
-1)o ft h e
hyperbolic tangent curve [Eq. 2]; SP: Peripheral sensitivity to insulin (adimensional; 0.0
≤ SP ≤ 1.0); Sh: Hepatic sensitivity to insulin (adimensional; 0.0 ≤ Sh ≤ 1.0); τ: (greek
letter tau). Time constant (minutes) [Eq. 1]; TD: Transport lag (minutes) [Eq. 1]
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